BACKGROUND/AIMS: To identify prodromal Alzheimer's disease (AD) subjects using a data-driven approach to determine cognitive profiles in mild cognitive impairment (MCI). METHODS: A total of 881 MCI subjects were recruited from 20 memory clinics and followed for up to 5 years. Outcome measures included cognitive variables, conversion to AD, and biomarkers (e.g. CSF, and MRI markers). Two hierarchical cluster analyses (HCA) were performed to identify clusters of subjects with distinct cognitive profiles. The first HCA included all subjects with complete cognitive data, whereas the second one selected subjects with very mild MCI (MMSE ≥28). ANOVAs and ANCOVAs were computed to examine whether the clusters differed with regard to conversion to AD, and to AD-specific biomarkers. RESULTS: The HCAs identified 4-cluster solutions that best reflected the sample structure. One cluster (aMCIsingle) had a significantly higher conversion rate (19%), compared to subjective cognitive impairment (SCI, p < 0.0001), and non-amnestic MCI (naMCI, p = 0.012). This cluster was the only one showing a significantly different biomarker profile (Aβ42, t-tau, APOE ε4, and medial temporal atrophy), compared to SCI or naMCI. CONCLUSION: In subjects with mild MCI, the single-domain amnestic MCI profile was associated with the highest risk of conversion, even if memory impairment did not necessarily cross specific cut-off points. A cognitive profile characterized by isolated memory deficits may be sufficient to warrant applying prevention strategies in MCI, whether or not memory performance lies below specific z-scores. This is supported by our preliminary biomarker analyses. However, further analyses with bigger samples are needed to corroborate these findings.
BACKGROUND/AIMS: To identify prodromal Alzheimer's disease (AD) subjects using a data-driven approach to determine cognitive profiles in mild cognitive impairment (MCI). METHODS: A total of 881 MCI subjects were recruited from 20 memory clinics and followed for up to 5 years. Outcome measures included cognitive variables, conversion to AD, and biomarkers (e.g. CSF, and MRI markers). Two hierarchical cluster analyses (HCA) were performed to identify clusters of subjects with distinct cognitive profiles. The first HCA included all subjects with complete cognitive data, whereas the second one selected subjects with very mild MCI (MMSE ≥28). ANOVAs and ANCOVAs were computed to examine whether the clusters differed with regard to conversion to AD, and to AD-specific biomarkers. RESULTS: The HCAs identified 4-cluster solutions that best reflected the sample structure. One cluster (aMCIsingle) had a significantly higher conversion rate (19%), compared to subjective cognitive impairment (SCI, p < 0.0001), and non-amnestic MCI (naMCI, p = 0.012). This cluster was the only one showing a significantly different biomarker profile (Aβ42, t-tau, APOE ε4, and medial temporal atrophy), compared to SCI or naMCI. CONCLUSION: In subjects with mild MCI, the single-domain amnestic MCI profile was associated with the highest risk of conversion, even if memory impairment did not necessarily cross specific cut-off points. A cognitive profile characterized by isolated memory deficits may be sufficient to warrant applying prevention strategies in MCI, whether or not memory performance lies below specific z-scores. This is supported by our preliminary biomarker analyses. However, further analyses with bigger samples are needed to corroborate these findings.
Authors: Mary M Machulda; Emily S Lundt; Sabrina M Albertson; Walter K Kremers; Michelle M Mielke; David S Knopman; Mark W Bondi; Ronald C Petersen Journal: Alzheimers Dement Date: 2019-05-23 Impact factor: 21.566
Authors: David P Sheppard; Jennifer E Iudicello; Mark W Bondi; Katie L Doyle; Erin E Morgan; Paul J Massman; Paul E Gilbert; Steven Paul Woods Journal: J Neurovirol Date: 2015-07-03 Impact factor: 2.643
Authors: Omar A Ibrahim; Sunyang Fu; Maria Vassilaki; Ronald C Petersen; Michelle M Mielke; Jennifer St Sauver; Sunghwan Sohn Journal: Proceedings (IEEE Int Conf Bioinformatics Biomed) Date: 2021-12
Authors: Kathryn N Devlin; Laura Brennan; Laura Saad; Tania Giovannetti; Roy H Hamilton; David A Wolk; Sharon X Xie; Dawn Mechanic-Hamilton Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.472
Authors: Anders Wallin; Arto Nordlund; Michael Jonsson; Kaj Blennow; Henrik Zetterberg; Annika Öhrfelt; Jacob Stålhammar; Marie Eckerström; Mårten Carlsson; Erik Olsson; Mattias Göthlin; Johan Svensson; Sindre Rolstad; Carl Eckerström; Maria Bjerke Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Lora Minkova; Elisa Scheller; Jessica Peter; Ahmed Abdulkadir; Christoph P Kaller; Raymund A Roos; Alexandra Durr; Blair R Leavitt; Sarah J Tabrizi; Stefan Klöppel Journal: Front Hum Neurosci Date: 2015-11-25 Impact factor: 3.169